Abstract |
Abnormal activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome is closely associated with a variety of inflammatory diseases. Herein, we describe the discovery and optimization of a series of NLRP3 inflammasome inhibitors based on the oridonin skeleton. These inhibitors exhibited moderate to potent inhibitory activity against interleukin 1β (IL-1β) release. Compound E6 showed the strongest inhibitory activity and better safety range against IL-1β (IC50 = 0.45 ± 0.02 μM, selectivity index = 36.49). Compared with oridonin, the activity and selectivity index of compound E6 increased 11.5 and 7.2 times, respectively. Compound E6 also exhibited broad-spectrum activity and specificity. Compound E6 mainly reduced the release of IL-1β by targeting the NLRP3 protein, thereby inhibiting the NLRP3-caspase 1-gasdermin D (GSDMD), as well as inhibiting the caspase 4-GSDMD signaling pathway. Further studies revealed an important therapeutic effect of E6 on dextran sulfate sodium-induced colitis. Compound E6 may be promising for the treatment of NLRP3-related diseases including inflammatory bowel disease.
|
Authors | Lei Pang, Hongmei Liu, Hongyu Quan, Hehuan Sui, Yi Jia |
Journal | European journal of medicinal chemistry
(Eur J Med Chem)
Vol. 245
Issue Pt 2
Pg. 114919
(Jan 05 2023)
ISSN: 1768-3254 [Electronic] France |
PMID | 36399877
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Inflammasomes
- oridonin
- NLR Family, Pyrin Domain-Containing 3 Protein
- Dextran Sulfate
|
Topics |
- Humans
- Inflammasomes
- NLR Family, Pyrin Domain-Containing 3 Protein
- Dextran Sulfate
- Colitis
(chemically induced, drug therapy)
|